Zoetis: A High-Quality Compounder Now On Sale?

Core Insights - Zoetis (ZTS) is facing stock pressure due to softer clinic traffic and uneven companion-animal demand, but its fundamentals remain strong, suggesting a potential discount for investors [2][4][10] - The company reported a 10% increase in organic operational revenue from livestock in Q3 2025, driven by vaccine demand, and a 7% operational expansion in the Simparica franchise [3][4] - Despite a narrowed full-year revenue guidance, new product approvals and initiatives are in place to stabilize and drive future growth [4][10] Financial Performance - Overall organic revenue growth was 4%, with a notable 9% organic increase in adjusted net income, indicating effective cost management [3][4] - Operating cash flow margin is nearly 31.0%, and operating margin stands at 37.6% for the last twelve months [10] - The stock is currently available at a price-to-sales (P/S) multiple of 5.7, representing a 35% discount compared to one year ago [10] Market Position - Zoetis is recognized as the world's largest animal-health company, with a strong history of high margins and steady cash generation [2] - The company has a long-standing leadership position in the animal health sector, which is being reassessed by investors due to current valuation levels [2][10] - The Trefis High Quality Portfolio, which includes Zoetis, has historically outperformed benchmark indices, indicating strong market positioning [9]